These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 3247706)

  • 1. [Treatment of Raynaud's syndrome in systemic connective tissue diseases with calcium antagonists].
    Shcherbakov AB
    Vutr Boles; 1988; 27(6):55-8. PubMed ID: 3247706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of Raynaud's syndrome with calcium entry blockers].
    Shcherbakov AB; Guseva NG; Mach ES
    Ter Arkh; 1987; 59(4):89-92. PubMed ID: 3296288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Calcium antagonists and Raynaud's phenomenon].
    Hachulla E; Devulder B
    Therapie; 1993; 48 Spec No():707-11. PubMed ID: 8091357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nifedipine and Raynaud's phenomenon associated with connective tissue diseases.
    Kahan A; Weber S; Amor B; Menkes CJ; Hodara M; Degeorges M
    Int Angiol; 1985; 4(2):221-3. PubMed ID: 3831143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Calcium antagonists for the treatment of Raynaud's phenomenon].
    Müller-Bühl U; Diehm C; Scheuermann W; Mörl H
    Dtsch Med Wochenschr; 1983 Nov; 108(47):1795-7. PubMed ID: 6357692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Controlled study of nifedipine in the treatment of Raynaud's phenomenon].
    Kahan A; Weber S; Amor B; Saporta L; Hodara M; Degeorges M
    Rev Rhum Mal Osteoartic; 1982 Apr; 49(5):337-43. PubMed ID: 6285445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular response of Raynaud's phenomenon to nifedipine or herbal medication (duhuo-tisheng tang with danggui-sini tang): a preliminary study.
    Wu YJ; Luo SF; Yang SH; Chen JY; Yu KH; See LC
    Chang Gung Med J; 2008; 31(5):492-502. PubMed ID: 19097597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study.
    Finch MB; Dawson J; Johnston GD
    Clin Rheumatol; 1986 Dec; 5(4):493-8. PubMed ID: 3816096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nifedipine in Raynaud's phenomenon: relationship between immediate, short term and longterm effects.
    Kallenberg CG; Wouda AA; Kuitert JJ; Tijssen J; Wesseling H
    J Rheumatol; 1987 Apr; 14(2):284-90. PubMed ID: 3598997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nifedipine in the treatment of idiopathic Raynaud's syndrome.
    Sarkozi J; Bookman AA; Mahon W; Ramsay C; Detsky AS; Keystone EC
    J Rheumatol; 1986 Apr; 13(2):331-6. PubMed ID: 3723496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers.
    Smith CR; Rodeheffer RJ
    Am J Cardiol; 1985 Jan; 55(3):154B-157B. PubMed ID: 3881908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The therapy of Raynaud's phenomenon].
    Di Giacinto G
    Clin Ter; 1993 Feb; 142(2):161-74. PubMed ID: 8472530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Corinfar in the treatment of Raynaud's syndrome in systemic scleroderma (preliminary results)].
    Shcherbakov AB; Guseva NG; Mach ES
    Ter Arkh; 1985; 57(5):141-4. PubMed ID: 4023933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis and treatment of Raynaud's phenomenon].
    Guilmot JL; Diot E; Lasfargues G
    Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1755-60. PubMed ID: 1685081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Action of nifedipine on the post-ischemic cold hyperemia reaction in Raynaud's phenomenon].
    Vayssairat M; Blaison N; Baudot N; Evenou P; Gilard M; Mathieu JF
    J Mal Vasc; 1989; 14(4):299-302. PubMed ID: 2584886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
    Rychlik-Golema W; Mastej K; Adamiec R
    Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Raynaud's phenomenon with calcium channel blockers.
    Smith CR; Rodeheffer RJ
    Am J Med; 1985 Feb; 78(2B):39-42. PubMed ID: 3976694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.